We are live on ! Find out more
NRXP icon

NRX Pharmaceuticals
NRXP

13 hedge funds and large institutions have $25.5M invested in NRX Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.77% less ownership

Funds ownership: 4.93% → 4.16% (-0.77%)

13% less funds holding

Funds holding: 15 → 13 (-2)

21% less capital invested

Capital invested by funds: $32.4M → $25.5M (-$6.91M)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

Holders
13
Holders Change
-2
Holders Change %
-13.33%
% of All Funds
0.26%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
2
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PMAM
Picton Mahoney Asset Management
Ontario, Canada
+$281K
2
UBS Group
UBS Group
Switzerland
+$2.11K

Top Sellers

Rank Fund Capital Flow
1
MSU
Mizuho Securities USA
New York
-$3.21M
2
WCMNY
Westchester Capital Management (New York)
New York
-$2.59M
3
WAM
Weiss Asset Management
Massachusetts
-$1.71M
4
OAM
Oxford Asset Management
United Kingdom
-$1.07M
5
BFM
Boothbay Fund Management
New York
-$1.06M
Name Holding Trade Value Shares
Change 		Change in
Stake
PAMP
1
Polar Asset Management Partners
Ontario, Canada
$5.49M – – –
MF
2
Magnetar Financial
Illinois
$4.93M – – –
OAM
3
Oxford Asset Management
United Kingdom
$4.58M -$1.07M -10,147 -19%
RCM
4
Rivernorth Capital Management
Florida
$2.54M – – –
AA
5
AQR Arbitrage
Connecticut
$2.12M – – –
KPF
6
K2 Principal Fund
Ontario, Canada
$2.05M – – –
YCM
7
Yakira Capital Management
Connecticut
$1.75M – – –
VOAM
8
Vertex One Asset Management
British Columbia, Canada
$1.06M – – –
WAM
9
Weiss Asset Management
Massachusetts
$876K -$1.71M -16,177 -66%
PMAM
10
Picton Mahoney Asset Management
Ontario, Canada
$97K +$281K +2,660 New
UBS Group
11
UBS Group
Switzerland
$18K +$2.11K +20 +13%
BCM
12
Bluefin Capital Management
New York
$16K – – –
Carson Wealth (CWM LLC)
13
Carson Wealth (CWM LLC)
Nebraska
$4K – – –
MSU
14
Mizuho Securities USA
New York
– -$3.21M -30,306 Closed
WCMNY
15
Westchester Capital Management (New York)
New York
– -$2.59M -24,466 Closed
BFM
16
Boothbay Fund Management
New York
– -$1.06M -10,000 Closed

NRXP Hedge Fund Activity: Q4 2019 in Review

13 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals (NRXP) for Q4 2019, worth a combined $25.5M — down 21% from $32.4M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of NRXP and 1 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 1 added.

The largest buyer was Picton Mahoney Asset Management, opening a new position worth an estimated $281K. The largest seller was Mizuho Securities USA, exiting entirely with an estimated $3.21M sold.

  • 13 institutional investors held NRX Pharmaceuticals (NRXP) as of Q4 2019, down from 15 in Q3 2019.
  • Funds reported $25.5M of NRX Pharmaceuticals stock for Q4 2019, down 21% quarter-over-quarter.
  • 1 fund opened new NRX Pharmaceuticals positions in Q4 2019 and 3 closed out, a net change of -2 holders.
  • The largest NRX Pharmaceuticals buyer in Q4 2019 was Picton Mahoney Asset Management, an estimated $281K added.
  • The largest NRX Pharmaceuticals seller in Q4 2019 was Mizuho Securities USA, an estimated $3.21M sold.

Based on aggregated 13F filings for Q4 2019.